Compositions and methods for improved car-T cell therapies
US10688166B2 · kind B2 · utility
0Cited by
13References
39Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 2, 2015 |
| Grant date | Jun 23, 2020 |
| Priority date | — |
| Expiry date | Nov 2, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2529/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the preparation and use in recipients of CAR-T cell-derived effector cells which are modified to limit their proliferation within the recipient. This is accomplished through the introduction of adducts into the nucleic acids of CAR-T cell-derived effector cells following expansion in vitro to provide expanded and activated CAR-T cell-derived effector cells that retain immunologic function, including the expression of one ore more cytokines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.